|
Stand UP to Rheumatoid Arthritis (SUPRA)
RECRUITINGN/ASponsored by Marie Hudson, MD
Actively Recruiting
PhaseN/A
SponsorMarie Hudson, MD
Started2023-02-01
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05305066
Summary
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Age ≥ 18 years; * Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA; * Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2). Exclusion Criteria: * Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2; * Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation; * Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis; * Unable to provide consent or complete forms (alone or with assistance) in English or French
Conditions2
ArthritisRheumatoid Arthritis
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorMarie Hudson, MD
Started2023-02-01
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05305066